Why 'Diabetes Insipidus' Was Renamed Arginine Vasopressin Deficiency (AVP-D)

In 2022 a multi-society working group proposed retiring "diabetes insipidus" in favor of two etiology-based names: arginine vasopressin deficiency (AVP-D) for the central form and arginine vasopressin resistance (AVP-R) for the nephrogenic form. The driving argument was patient safety, because confusion with the far more common diabetes mellitus has led clinicians to withhold desmopressin, with documented cases of severe dehydration and death. The proposal appeared in Endocrine Connections and several sister journals, and it was endorsed by most of the major endocrine societies.

What actually changed, and what did not

The disorder itself is unchanged. "Diabetes insipidus" has always described a syndrome of large-volume dilute urine driven either by insufficient secretion of the antidiuretic hormone arginine vasopressin (the central or cranial form) or by kidneys that cannot respond to it (the nephrogenic form). The old name is a historical artifact. "Diabetes" comes from a Greek word for a siphon, describing heavy urination, and "insipidus" means tasteless, distinguishing dilute urine from the sugary urine of "diabetes mellitus." Two conditions that share almost no biology ended up sharing a first name for reasons that made sense to eighteenth-century physicians who tasted urine and made little sense to anyone since.

The 2022 position statement, produced by the Working Group for Renaming Diabetes Insipidus and counting endocrinologists Mirjam Christ-Crain and Joseph Verbalis among its leading figures, argued that a disease name should point at mechanism. AVP-D names the missing hormone. AVP-R names the resistance to it. The labels are descriptive rather than eponymous, and they separate a pituitary problem from a kidney problem that the single old term blurred together.

The safety case is the strongest part

The most persuasive evidence here is clinical rather than linguistic. Because the word "diabetes" dominates the old name, patients admitted to hospital have been repeatedly mistaken for having type 1 or type 2 diabetes. That mistake has consequences. Someone with central AVP-D depends on scheduled desmopressin to hold onto water, and missing even a dose or two can produce dangerous dehydration within hours.

The scale of the problem was quantified before the rename. A patient-perspective survey of 1,034 people with central diabetes insipidus, published in The Lancet Diabetes and Endocrinology in 2022, found that roughly 80 percent had encountered a situation where their condition was confused with diabetes mellitus by a health professional, and about 85 percent supported changing the name. Separately, a 2016 NHS England patient safety alert had already flagged the risk of severe harm or death when desmopressin is omitted or delayed in people with cranial diabetes insipidus, citing reports of dosing errors and incidents in which omission led to severe dehydration and death. That combination, a large majority of patients reporting confusion and a national body documenting deaths, is what elevated a naming preference into a safety question.

I find this the appraisable core of the proposal. The claim is not that a new name treats anyone. The claim is that a clearer name reduces a specific, recurring, sometimes lethal error at the bedside. That is a testable hypothesis about human factors, and the direction of the survey evidence supports it, even though no one has run a trial showing that the rename itself lowers mortality.

Endorsement is broad, but the coding lags

The societies backing the change include the Endocrine Society, the European Society of Endocrinology, the Pituitary Society, the Society for Endocrinology, the European Society for Paediatric Endocrinology, the Endocrine Society of Australia, the Brazilian Society of Endocrinology and Metabolism, and the Japan Endocrine Society. That is unusually wide agreement for a terminology question.

Agreement among societies is not the same as adoption across the health system. Terminology lives inside code sets, electronic records, laboratory menus, insurance forms, and textbooks, and those move slowly. The working group submitted a request to update the WHO's ICD-11 classification, and it recommended a transitional dual format in the meantime: "AVP deficiency (cranial diabetes insipidus)" and "AVP resistance (nephrogenic diabetes insipidus)," keeping the old term in parentheses so that a reader who only knows the legacy name is not lost. The tradeoff is direct. Dropping the old word entirely maximizes the safety benefit but risks a transition period where records, clinicians, and patients use different vocabularies for the same disease. Carrying both terms preserves continuity while diluting the very clarity the change is meant to deliver. The dual format is a deliberate compromise, and until ICD-11 and downstream systems fully absorb AVP-D and AVP-R, patients will keep seeing the old name on paperwork.

What this means if you carry the diagnosis

If your records say diabetes insipidus, AVP-D, or AVP-R, they can all refer to the same condition you already have, and nothing about your physiology changed in 2022. The practical value of the newer terms is communication. Being able to tell an unfamiliar clinician "I have arginine vasopressin deficiency, not diabetes," and to stress that a missed desmopressin dose is an emergency, addresses exactly the confusion the rename was designed to prevent. This article is educational and is not medical advice; how your own condition is labeled, monitored, and treated is a decision for you and your clinician. Whether the field lands on the new names quickly or slowly, the underlying lesson is durable: names are part of how medicine transmits information, and when a name misfires, the fix is worth taking seriously.